All Oncology News

Selinexor plus ruxolitinib met the SVR co–primary end point but missed the symptom score end point in the phase 3 SENTRY trial in myelofibrosis.

Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.

Rapcabtagene autoleucel exhibited promising response and safety data in relapsed or refractory B-cell acute lymphoblastic leukemia.

Tebentafusp use was associated with frequent dermatologic AEs, with desquamation and hypopigmentation observed in non-White patients in a real-world analysis.

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

Sensitivity analyses accounting for new primary melanoma did not diminish the RFS benefit favoring adjuvant pembrolizumab vs placebo in high-risk stage II melanoma.

PFS was improved when patients with advanced EGFR exon 20 insertion–positive NSCLC received sunvozertinib vs platinum chemotherapy in the first line.

Tafasitamab has been approved by ANVISA for the treatment of relapsed or refractory follicular lymphoma.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

Chemo therapy delivered in the home of patients has shown feasibility and safety according to researchers at Mayo Clinic

Limited knowledge of long-term irAEs points to the need for more concentrated research regarding optimal postimmunotherapy toxicity management.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Pathologists play a key role in lung cancer care, from biomarker testing to tissue triage.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

The FDA has approved nivolumab plus AVD for adult and pediatric patients with previously untreated, stage III or IV classical Hodgkin lymphoma.

CNS-penetrant TKIs are reshaping brain metastases care in lung cancer, shifting sequencing decisions between systemic and local therapy.

Jorge Cortes, MD, discusses available TKIs and how to navigate optimal treatment selection for patients with chronic myeloid leukemia.

Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

The phase 3 TALAPRO-3 study evaluating talazoparib plus enzalutamide HRR gene–mutated mCSPC met its primary end point.

A new gene-editing approach developed at UCSF treated leukemia, multiple myeloma, and sarcoma in mice by precisely reprogramming immune cells with no external manufacturing required.

Nicole Lamanna, MD, discusses both CLL 17 and FLAIR studies and their significance for chronic lymphocytic leukemia.

Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

However, a trend towards OS benefit was observed when treatment with cabozantinib was deferred until after disease progression vs administered upfront.

First-line sacituzumab govitecan plus pembrolizumab generated efficacy and safety improvements vs chemotherapy plus pembrolizumab in PD-L1–positive mTNBC.

David B. Solit, MD, discusses ongoing efforts to develop ADCs and other novel treatment approaches beyond EV plus pembrolizumab in urothelial cancer.